Thyroid Pharmacology

Correct Answer

B — Liquid levothyroxine solution

Rationale

Liquid levothyroxine solution is the liquid oral formulation of levothyroxine. The standard preparation is the tablet, which requires an acidic gastric environment for dissolution. Intravenous levothyroxine is a parenteral preparation used in myxedema coma, not an oral formulation. Liothyronine is a separate thyroid hormone preparation — synthetic triiodothyronine — available as a tablet but classified as a different drug entirely.

Correct Answer

D — Intravenous infusion with a loading dose followed by daily maintenance doses

Rationale

Myxedema coma requires intravenous levothyroxine because gastrointestinal absorption is unreliable in a comatose or hemodynamically unstable patient with reduced gut motility. The standard protocol uses an intravenous loading dose of 300–500 micrograms to rapidly saturate the expanded volume of distribution, followed by 50–100 micrograms intravenously daily. Levothyroxine is not available as a subcutaneous injection or transdermal patch, and oral or nasogastric administration cannot be relied upon in this setting.

Correct Answer

A — Hydrocortisone

Rationale

Hydrocortisone is a glucocorticoid included in myxedema coma management to cover the risk of concurrent adrenal insufficiency — severely hypothyroid patients may have insufficient cortisol reserve to tolerate physiological stress. Methimazole is a thionamide antithyroid drug used in hyperthyroidism, not hypothyroidism. Potassium iodide is an iodide preparation used in thyrotoxicosis management. Propranolol is a beta-adrenergic receptor antagonist used as an adjunct in hyperthyroidism.

Correct Answer

C — Liothyronine

Rationale

Liothyronine is synthetic triiodothyronine and is used in myxedema coma for rapid triiodothyronine repletion. Its short half-life of approximately one day and higher bioavailability allow rapid achievement of active hormone levels without depending on peripheral conversion of thyroxine to triiodothyronine — a conversion that may be impaired in severe illness. Levothyroxine is synthetic thyroxine and is the standard replacement preparation for routine hypothyroidism management. Methimazole and propylthiouracil are thionamide antithyroid drugs used in hyperthyroidism.

Correct Answer

A — Lugol's iodine solution

Rationale

Lugol's iodine solution is an iodide preparation containing 5% iodine and 10% potassium iodide. It is used as an adjunct in hyperthyroidism to exploit the Wolff-Chaikoff effect and to reduce thyroid gland vascularity before surgery. Saturated solution of potassium iodide is the other major iodide preparation in this class. Levothyroxine is a thyroid hormone replacement. Methimazole is a thionamide antithyroid drug. Hydrocortisone is a glucocorticoid — none of these are iodide preparations.

Correct Answer

D — Cholestyramine

Rationale

Cholestyramine is a bile acid sequestrant that binds thyroid hormone in the intestinal lumen, interrupting enterohepatic recirculation and reducing the circulating hormone pool. It is used as an adjunct in severe or refractory thyrotoxicosis to accelerate hormone clearance. Propranolol is a beta-adrenergic receptor antagonist. Methimazole is a thionamide that blocks new hormone synthesis. Hydrocortisone is a glucocorticoid. None of these are bile acid sequestrants.

Correct Answer

C — Adipose tissue does not proportionally increase levothyroxine metabolism, so dosing by total body weight would cause overreplacement

Rationale

The standard full replacement dose of levothyroxine is approximately 1.6 micrograms per kilogram per day. In obese patients, adipose tissue does not proportionally increase thyroxine metabolism or utilization — using total body weight would therefore deliver an excess dose relative to actual metabolic need, risking overreplacement and iatrogenic thyrotoxicosis. Lean body weight reflects the metabolically active tissue mass that drives levothyroxine requirements. Levothyroxine is not produced in adipose tissue, does not accumulate excessively in fat, and is not renally cleared in a way that would require dose reduction in obesity.

Correct Answer

B — Estrogen increases thyroxine-binding globulin, expanding the bound hormone pool, while the placenta also metabolizes thyroxine

Rationale

During pregnancy, estrogen stimulates hepatic production of thyroxine-binding globulin. The expanded binding protein pool sequesters thyroxine, transiently reducing free hormone levels and driving a compensatory increase in total thyroxine requirement. The placenta also expresses type 3 deiodinase, which inactivates thyroxine and triiodothyronine, adding a further metabolic burden. Together these mechanisms increase levothyroxine requirements by 30–50% beginning in the first trimester. Thyroid-stimulating hormone is not suppressed by pregnancy in a way that would drive levothyroxine requirements upward.

Correct Answer

A — Low thyroid-stimulating hormone in elderly patients is associated with atrial fibrillation and bone mineral density loss

Rationale

In patients over 65, low thyroid-stimulating hormone — indicating relative thyroid hormone excess — is associated with increased risk of atrial fibrillation and accelerated bone mineral density loss, particularly in postmenopausal women. These risks outweigh the marginal benefit of targeting a lower thyroid-stimulating hormone in this age group. The higher target range (1.0–4.0 mIU/L) reflects this risk-benefit recalibration rather than any pharmacokinetic difference in levothyroxine handling. Pituitary feedback sensitivity is not the determining factor.

Correct Answer

D — Gastrointestinal absorption of levothyroxine is unreliable in an obtunded patient with reduced gut motility

Rationale

Myxedema coma produces reduced consciousness and hemodynamic instability that impair gut motility, making gastrointestinal absorption of levothyroxine unpredictable. Intravenous administration ensures reliable delivery of the large loading dose (300–500 micrograms) needed to rapidly saturate the expanded volume of distribution typical of severe hypothyroidism. Levothyroxine is not subject to first-pass metabolism in a way that would make intravenous administration superior on that basis, and the intravenous formulation does not contain liothyronine. Nasogastric levothyroxine is not absorbed too rapidly — unreliability, not speed, is the concern.

Correct Answer

C — Levothyroxine is recommended when thyroid-stimulating hormone is 4.5–10 mIU/L if symptoms, positive anti-thyroid peroxidase antibodies, dyslipidemia, or pregnancy are present

Rationale

Subclinical hypothyroidism management is risk-stratified by thyroid-stimulating hormone level and clinical context. Treatment is universally recommended when thyroid-stimulating hormone exceeds 10 mIU/L. When thyroid-stimulating hormone is between 4.5 and 10 mIU/L, treatment is recommended in younger patients who have symptoms attributable to hypothyroidism, positive anti-thyroid peroxidase antibodies (indicating Hashimoto's thyroiditis with likely progression), dyslipidemia that may be thyroid-driven, or pregnancy. In an asymptomatic patient with no additional risk factors, observation with monitoring is appropriate rather than immediate treatment.

Correct Answer

B — Roux-en-Y bypass reroutes intestinal flow past the proximal small intestine, where most levothyroxine absorption occurs

Rationale

Levothyroxine absorption occurs primarily in the proximal small intestine — the jejunum and, to a lesser extent, the duodenum. Roux-en-Y gastric bypass creates an anastomosis that reroutes ingested material past this primary absorption site, bypassing it in favor of a more distal intestinal segment with lower absorptive capacity for levothyroxine. Post-surgical patients typically require dose increases of 30–50% and should have thyroid-stimulating hormone checked every 6–12 months. Switching to liquid levothyroxine may further improve bioavailability in this population. Reduced gastric acid and transit time play secondary roles compared with the anatomical bypass of the absorptive segment.

Correct Answer

A — The damaged pituitary cannot mount a normal thyroid-stimulating hormone response to hormone deficiency, making thyroid-stimulating hormone an unreliable adequacy marker

Rationale

In central hypothyroidism, the pathology lies in the pituitary or hypothalamus rather than the thyroid gland. Because the pituitary is dysfunctional, it cannot generate the normal compensatory rise in thyroid-stimulating hormone that would signal inadequate thyroid hormone replacement. Thyroid-stimulating hormone may be low, inappropriately normal, or only mildly elevated even when the patient is underreplaced. Free thyroxine — targeted to the upper half of the normal reference range — becomes the primary biochemical monitor for dose adequacy in these patients.

Correct Answer

D — Liothyronine's half-life of approximately one day allows it to clear within two weeks, compared with four weeks required for levothyroxine's 6–7 day half-life

Rationale

The pharmacokinetic basis is straightforward: four to five half-lives are required to clear any drug to negligible levels. Levothyroxine's half-life of 6–7 days requires approximately 28–35 days (four weeks) of withdrawal before thyroid-stimulating hormone rises adequately. Liothyronine's half-life of approximately one day requires only four to five days for clearance — well within a two-week withdrawal window — producing the same thyroid-stimulating hormone rise with less cumulative hypothyroid symptom burden. The substitution protocol exploits this pharmacokinetic difference to minimize the duration of symptomatic hypothyroidism before scanning.

Correct Answer

B — Elevated gastric pH impairs standard tablet dissolution and reduces levothyroxine absorption; switching to liquid levothyroxine would restore bioavailability

Rationale

Standard levothyroxine tablets require an acidic gastric environment for dissolution. Proton pump inhibitors suppress parietal cell acid secretion, raising gastric pH and impairing tablet dissolution — reducing levothyroxine bioavailability and producing the pattern of dose-resistant hypothyroidism seen here. Liquid levothyroxine solution is minimally affected by gastric pH and restores consistent absorption in this setting. The management also includes confirming the patient takes levothyroxine on an empty stomach, separated from the proton pump inhibitor. Proton pump inhibitors do not induce hepatic enzymes, compete for intestinal transporters, or increase thyroxine-binding globulin.

Correct Answer

C — Excess thyroid hormone activates thyroid hormone receptor alpha-1 in the heart, increasing heart rate, atrial ectopy, and susceptibility to fibrillation

Rationale

Thyroid hormone receptor alpha-1 predominates in the heart. Excess thyroid hormone at this receptor increases heart rate, left ventricular mass, and cardiac contractility, while also increasing atrial ectopy and shortening atrial refractory periods — all of which predispose to atrial fibrillation. In patients over 60 on suppressive levothyroxine therapy, the risk of atrial fibrillation is two to threefold higher than in age-matched controls. The appropriate response is to de-escalate the thyroid-stimulating hormone suppression target to the lowest level consistent with cancer surveillance goals. Thyroxine does not block cardiac potassium channels directly or act through atrial natriuretic peptide suppression.

Correct Answer

A — Maternal thyroid-stimulating hormone receptor antibodies cross the placenta and can stimulate the fetal thyroid, causing neonatal Graves disease

Rationale

Thyroid-stimulating hormone receptor antibodies are immunoglobulin G antibodies that cross the placenta via active Fc receptor-mediated transport. When maternal titers exceed three times the upper reference limit at 28–32 weeks, the concentration reaching the fetal circulation is sufficient to activate fetal thyroid-stimulating hormone receptors and drive autonomous fetal thyroid hormone synthesis — the mechanism of neonatal Graves disease. This finding mandates close neonatal monitoring with thyroid function testing at 48–72 hours and again at 7–10 days of life, because clinical thyrotoxicosis may be delayed 3–7 days if the mother has been on antithyroid drugs that clear from the neonate over the first week. The antibodies stimulate rather than suppress or block fetal thyroid function.

Correct Answer

D — Thyroid hormone increases cardiac oxygen demand by raising heart rate and contractility, which can exceed supply in a patient with fixed coronary obstruction

Rationale

Thyroid hormone receptor alpha-1 in the heart mediates increases in heart rate, stroke volume, and myocardial contractility — all of which raise cardiac oxygen demand. In a patient with underlying coronary artery disease and fixed obstruction, the supply-demand mismatch created by rising thyroid hormone levels can precipitate angina or myocardial infarction. This is the pharmacological basis for the standard recommendation to initiate levothyroxine at low doses (12.5–25 micrograms per day) with slow uptitration in patients with cardiac disease, even in the setting of severe hypothyroidism, targeting the lower end of the age-appropriate thyroid-stimulating hormone range. Thyroid hormone does not cause coronary vasospasm, displace lipoproteins via thyroxine-binding globulin, or act through medication absorption normalization.